Compare Tidewater Inc (TDW) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tidewater Inc vs BIO-TECHNE Corp — how do they compare? Tidewater Inc trades at $78.18 (market cap $3.75B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: BIO-TECHNE Corp is far larger — about 3× Tidewater Inc's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Tidewater Inc pays none. Which is the better fit depends on your goals.
| TDW | TECH | |
|---|---|---|
Market Cap | $3.75B | $11.16B |
Sector | Utilities | Health |
52-Week High | $91.12 | $72.12 |
52-Week Low | $47.29 | $43.31 |
Enterprise Value | $3.85B | $11.24B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tidewater (TDW) trades at $75.43, down 0.51% today, with a bullish technical outlook supported by moving averages but recent earnings misses in Q1 and Q4 2026. The company maintains strong profitability with a 22.16% net margin and a P/E of 12.79, while news highlights an acquisition by FTAI Infrastructure (GlobeNewsWire, June 29, 2026).
Outlook is mixed: valuation appears reasonable with solid cash flow, but earnings volatility and sector headwinds pose risks. Analyst consensus leans hold (61.54%), suggesting cautious optimism amid execution challenges.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
